DNA binding, cleavage and cytotoxicity of a novel dimetallic Fe(III) triaza-cyclononane complex
View/ Open
Date
2016-03-03Author
Araujo, Thaylan Pinheiro
Gandin, Valentina
Kavanagh, Paul
Braude, Jeremy Phillip
Nodari, Luca
Montagner, Diego
Erxleben, Andrea
Metadata
Show full item recordUsage
This item's downloads: 340 (view details)
Cited 2 times in Scopus (view citations)
Recommended Citation
Pinheiro Araujo, Thaylan, Gandin, Valentina, Kavanagh, Paul, Braude, Jeremy Phillip, Nodari, Luca, Montagner, Diego, & Erxleben, Andrea. (2016). DNA binding, cleavage and cytotoxicity of a novel dimetallic Fe(III) triaza-cyclononane complex. Inorganica Chimica Acta, 452, 170-175. doi: https://doi.org/10.1016/j.ica.2016.02.044
Published Version
Abstract
A novel bimetallic Fe(III) complex with the bis(triaza-cyclononane) ligand 2,6-bis(1,4,7-triazacyclonon-1-ylmethyl)-4-methylphenol (bcmp) is reported. [Fe-2(bcmp(-H))(mu-OH)Cl-2]Cl-2 (2) contains two octahedral Fe(III) centers bound to the two triaza-cyclononane rings of bcmp. The coordination sphere is completed by one chlorine, one bridging phenolate oxygen and one bridging hydroxide group. The complex has been characterized by elemental analysis, Mossbauer spectroscopy, UV-Vis spectroscopy, pH potentiometric titration, ESI mass spectrometry and cyclic voltammetry. The complex hydrolyzes the DNA model bis (2,4-dinitrophenyl) phosphate (BDNPP) with a maximum activity a pH 7. Michaelis-Menten behavior is observed with k(cat) = 3.56 x 10(-4)s(-1) and K-m = 0.56 mM (pH 7.0, 40 degrees C). The interaction of 2 with CT DNA was studied by electronic absorption spectroscopy and gel electrophoresis. Notably, the complex relaxes supercoiled pUC19 DNA into the nicked form at low micromolar concentration (10 mu M) in the presence of an external reducing agent (ascorbic acid). Finally, the in vitro antiproliferative activity of 2 was assessed on a panel of human cancer cell lines and results revealed that the complex exhibited a significant cytotoxic effects in particular versus colon LoVo cancer cells, wih IC50 value 2.5 times lower than that shown by the reference metallodrug cisplatin (3.54 versus 8.53 mu M). (C) 2016 Elsevier B.V. All rights reserved.